Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF).
The company has received US FDA clearance to proceed with Phase 2 clinical trials for its Ras pathway inhibitor, PTX-100.
This study will focus on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL).
The decision follows the completion of a Phase 1b trial involving 19 T-cell lymphoma patients, which demonstrated an excellent safety profile and a 42% overall response rate.
Among evaluable r/r CTCL patients, five of seven experienced clinical benefits.
The global Phase 2 trial will enrol 115 patients across 15 sites in Australia, the US and Europe.
It will consist of two parts: dose optimisation and efficacy assessments. Primary endpoints include objective response rate, with secondary metrics focusing on progression-free survival, overall survival, safety, and quality of life.
The company describes FDA clearance as a transformative milestone, reflecting years of preclinical and clinical development.
Prescient aims to collaborate with global CTCL experts to deliver a safe and effective therapy for this area of unmet need. The announcement drove a 55% surge in the company’s shares.